toposide + anrotinib + emvolizumab

This is a combination regimen consisting of three agents: - **Toposide** (commonly known as etoposide): a small molecule chemotherapeutic agent that inhibits DNA topoisomerase II, leading to DNA strand breaks and apoptosis in rapidly dividing cells. - **Anrotinib**: a small molecule multi-targeted tyrosine kinase inhibitor that primarily targets vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit, thereby inhibiting tumor angiogenesis and cell proliferation. - **Emvolizumab**: There is no evidence in the provided sources or current scientific literature for a drug named "emvolizumab." It may be a misspelling or confusion with another monoclonal antibody such as pembrolizumab. If "emvolizumab" refers to pembrolizumab, then it is an anti-PD-1 monoclonal antibody immune checkpoint inhibitor that blocks the PD-1 receptor on T cells, enhancing immune-mediated tumor cell killing[2][3][4][5][7].